Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-117 fixed-dose placebo-controlled phase 2 study in adults with major depressive disorder
2017-005149-64Phase 2Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of min-117 in major depressive disorder (MDD), sponsored by Minerva Neurosciences, Inc.. Started Apr 2018; status: completed.
02
Drugs
min-117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-005149-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005149-64.